R Tony Tripeny Purchases 900 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director R Tony Tripeny acquired 900 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was bought at an average cost of $113.69 per share, for a total transaction of $102,321.00. Following the completion of the transaction, the director directly owned 6,298 shares of the company’s stock, valued at $716,019.62. This trade represents a 16.67% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mesa Laboratories Stock Up 2.0%

Shares of NASDAQ MLAB traded up $2.15 on Monday, hitting $108.19. The company had a trading volume of 77,359 shares, compared to its average volume of 147,914. Mesa Laboratories, Inc. has a 12-month low of $58.83 and a 12-month high of $115.52. The business has a 50 day moving average of $100.64 and a two-hundred day moving average of $96.07. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $605.40 million, a P/E ratio of 128.81 and a beta of 0.92.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 EPS for the quarter. The business had revenue of $60.14 million for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be given a $0.16 dividend. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 annualized dividend and a yield of 0.6%. Mesa Laboratories’s dividend payout ratio (DPR) is 76.19%.

Institutional Investors Weigh In On Mesa Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Mesa Laboratories by 4.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after buying an additional 143 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Mesa Laboratories by 1.5% in the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock worth $1,265,000 after buying an additional 194 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock worth $69,000 after buying an additional 243 shares during the last quarter. Deutsche Bank AG raised its holdings in Mesa Laboratories by 5.9% in the fourth quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier’s stock valued at $349,000 after acquiring an additional 248 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 322 shares in the last quarter. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on MLAB. Wall Street Zen cut shares of Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Finally, Wells Fargo & Company lifted their price target on shares of Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $110.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.